|
US2014058068A1
|
|
GH-RH analogs with potent agonistic effects
|
|
US2013195807A1
|
|
Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
|
|
US8507433B1
|
|
Cardioprotective effects of GHRH agonists
|
|
US2013261055A1
|
|
N- and C- terminal substituted antagonistic analogs of GH-RH
|
|
WO2011034976A1
|
|
Fluorinated ghrh antagonists
|
|
WO2009120831A2
|
|
Novel n-and c-terminal substituted -antagonistic analogs of human gh-rh
|
|
US4800191A
|
|
LHRH antagonists
|
|
US4650787A
|
|
Biologically active octapeptides
|
|
CS236662B2
|
|
Production method of peptides
|
|
YU255081A
|
|
Process for obtaining new anorexigenic peptides
|
|
HU183636B
|
|
Process for preparing new peptides with anorexigenic activity
|
|
DD202693A5
|
|
Method for the preparation of a peptide
|
|
FI813282L
|
|
Framstaellningsfoerfarande foer nya anorexigena peptider
|
|
SE8106127L
|
|
Anorectic di: or tri:peptide derivs. - contg. pyroglutamyl or homo:pyroglutamyl residue, useful for treating obesity, excessive gastric secretion etc.
|
|
NZ198646A
|
|
Pyroglutamyl tripeptides
|
|
ZA8107119B
|
|
Anorexigenic peptides
|
|
DK455581A
|
|
Procedure for preparing peptides or pharmacological acceptable salts thereof with acids
|
|
CA1189066A
|
|
Anorexigenic peptides
|
|
EP0041286A1
|
|
LH-RH antagonists
|
|
GB2053229A
|
|
Lh-rh antagonists
|
